Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis

Drugs

Volumn 67, Issue 8, 2007, Pages 1139-1147

  Coker, Robina K ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; HYDROXYCHLOROQUINE; INFLIXIMAB; LIPOPROTEIN; METHOTREXATE; PREDNISONE; RISEDRONIC ACID; VITAMIN D;

ACNE; ADRENAL INSUFFICIENCY; AVASCULAR NECROSIS; BONE NECROSIS; CATARACT; DEPRESSION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ETHNIC GROUP; EUPHORIA; FRACTURE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HIRSUTISM; HUMAN; HYPERCALCURIA; HYPERTENSION; HYPOKALEMIA; INFECTION; INFECTION RISK; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; LUNG DISEASE; LUNG PARENCHYMA; MONOTHERAPY; MYOPATHY; OSTEOPOROSIS; PATIENT CARE; PATIENT MONITORING; PEPTIC ULCER; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; RESPIRATORY FUNCTION; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN THINNING; SYMPTOM; TREATMENT DURATION; ULCER;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES; SARCOIDOSIS, PULMONARY;

EID: 34249878201     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767080-00004     Document Type: Review

References (31)

1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Am J Respir Crit Care Med 1999; 160: 736-55
2. Thomeer M, Demedts M, Wuyts W. Epidemiology of sarcoidosis. In: M Drent, U Costabel, editors. Sarcoidosis. European Respiratory Monograph. Wakefield: European Respiratory Society, 2005 Sep; 32: 13-22
3. Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 46-52
4. Baughmann RP, Lower EE. Therapy for sarcoidosis. In: Drent M, Costabel U, editors. Sarcoidosis. European Respiratory Monograph. Wakefield: European Respiratory Society, Sep 2005; 32: 301-9
5. White, ES, Keena DT, Zisman DA, et al. Corticosteroid therapy for sarcoidosis. In: Baughmann RP, editor. Sarcoidosis. Lung biology in health and disease series, 2006; 210: 689-716
6. Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis-experience with thirty six cases. JAMA 1954; 156: 461-6
7. Siltzbach LE. Effects of cortisone in sarcoidosis: a study of 13 patients. Am J Med 1952; 12: 139-60
8. Odlum CM, Fitzgerald MX. Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis. Sarcoidosis 1986; 3: 40-6
9. Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28: 627-36
10. DeRemee RA. The present status of treatment with pulmonary sarcoidosis: a house divided. Chest 1977; 71: 288-93
11. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment. Thorax 1996; 51: 238-47
12. Gottlieb JE, Israel HL, Steiner M, et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-31
13. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults: British Thoracic Society recommendations. Thorax 1999 Apr; 54 Suppl. 1: S1-14
14. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287: 1301-7
15. Axelrod L. Glucocorticoid therapy. Medicine 1976; 55: 39-65
16. Spratling L, Tenholder MF, Underwood GH, et al. Daily vs alternate day prednisolone therapy for stage II sarcoidosis. Chest 1985; 88: 687-90
17. Selroos O. Use of budenoside in the treatment of pulmonary sarcoidosis. Ann NY Acad Sci 1986; 465: 713-21
18. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5: 106-10
19. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-8
20. Pietinalho A, Tukainen P, Haahtela T, et al. Finnish Pulmonary Sarcoidosis Study Group. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 1999; 116: 424-31
21. Pietinalho A, Tukainen P, Haahtela T, et al. The Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31
22. Milman N. Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis-a critical reappraisal. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 150-7
23. Agency for Health Care Policy and Research. Acute pain management, operative or medical procedures and trauma. Clinical practice guideline 92-0032. Rockville (MD): Agency for Healthcare Policy and Research Publications, 1992
24. Saag KG, Koenhke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23
25. Compston J. Guidelines for the management of osteoporosis: the present and the future. Osteoporos Int 2005; 16: 1173-6
26. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced Osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003; 163: 2619-24
27. American College of Rheumatology ad hoc committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503
28. The management of glucocorticoid-induced osteoporosis in men and women. London: Royal College of Physicians, 2002
29. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997; 61: 382-5
30. Sipahi S, Tuzun S, Ozaras R, et al. Bone mineral density in women with sarcoidosis. J Bone Miner Metab 2004; 22: 48-52
31. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dental Assoc 2005; 136: 1658-68